Introduction: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3, recently approved in Europe for the first-line treatment of metastatic renal cell carcinoma (mRCC). Methods: Retrospective analysis of safety and activity of tivozanib administered at 1.34 mg daily (3 weeks on, 1 week off) within a compassionate-use program to patients with mRCC with no prior systemic treatment in Italy. Results: From August 2018 to April 2019, 64 patients have started tivozanib in 9 oncology units. The median age was 67.5 years (range 40–85), 62.5% males. According to International Metastatic Renal Cell Carcinoma Database Consortium criteria, 27.1% of patients were good prognosis, 57.6% intermediate, and 15.3% poor. Primary tumor had been removed in 71.9% of patients. Histology was clear cell 89%, papillary 4.7%, and unclassified 6.3%. The response rate was 34.4%, stable disease 40.6%, and progression 15.6%. Grade 3–4 toxicities were 7.8% hypertension, 4.7% anemia, 3.1% mucositis, 3.1% asthenia, 1.6% diarrhea, 1.6% anorexia, 1.6% worsening of renal function, and 3.1% cardiac events. Dose reduction to 0.89 mg was applied to 17.2% of patients, and the discontinuation rate due to toxicity was 5.8%. Median progression-free survival was 12.4 months, with 68.7% of patients alive at 12 months. The developing of hypertension predicted increased progression-free survival at multivariate analysis (HR, 0.128; 95% CI, 0.03–0.59; p = 0.008). Conclusions: Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.

1.
Motzer
RJ
,
Hutson
TE
,
Cella
D
,
Reeves
J
,
Hawkins
R
,
Guo
J
,
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
.
N Engl J Med
.
2013
;
369
(
8
):
722
31
. .
2.
Heng
DY
,
Xie
W
,
Regan
MM
,
Regan
MM
,
Warren
MA
,
Golshayan
AR
,
Prognostic factors for overall survival in pts with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
.
J Clin Oncol
.
2009
;
27
:
5794
9
.
3.
Choueiri
TK
,
Halabi
S
,
Sanford
BL
,
Hahn
O
,
Michaelson
MD
,
Walsh
MK
,
Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial
.
J Clin Oncol
.
2017
;
35
(
6
):
591
7
. .
4.
Santoni
M
,
Massari
F
,
Piva
F
,
Carrozza
F
,
Di Nunno
V
,
Cimadamore
A
,
Tivozanib for the treatment of renal cell carcinoma
.
Expert Opin Pharmacother
.
2018
;
19
(
9
):
1021
5
. .
5.
Kalathil
SG
,
Wang
K
,
Hutson
A
,
Iyer
R
,
Thanavala
Y
.
Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients
.
Oncoimmunology
.
2020
;
9
(
1
):
1824863
. .
6.
Nosov
DA
,
Esteves
B
,
Lipatov
ON
,
Lyulko
AA
,
Anischenko
AA
,
Chacko
RT
,
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma
.
J Clin Oncol
.
2012
;
30
(
14
):
1678
85
. .
7.
Motzer
RJ
,
Nosov
D
,
Eisen
T
,
Bondarenko
I
,
Lesovoy
V
,
Lipatov
O
,
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial
.
J Clin Oncol
.
2013
;
31
(
30
):
3791
9
. .
8.
Molina
AM
,
Hutson
TE
,
Nosov
D
,
Tomczak
P
,
Lipatov
O
,
Sternberg
CN
,
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
.
Eur J Cancer
.
2018
;
94
:
87
94
. .
9.
Escudier
B
,
Porta
C
,
Eisen
T
,
Belsey
J
,
Gibson
D
,
Morgan
J
,
The role of tivozanib in advanced renal cell carcinoma therapy
.
Expert Rev Anticancer Ther
.
2018
;
18
(
11
):
1113
24
. .
10.
EMA product information for Tivozanib-FOTIVDA. Available from: https://www.ema.europa.eu/en/documents/product-information/fotivda-epar-product-information_en.pdf. Accessed 2021 Feb 6.
11.
Manz
KM
,
Fenchel
K
,
Eilers
A
,
Morgan
J
,
Wittling
K
,
Dempke
WCM
.
Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis
.
Adv Ther
.
2020
;
37
(
2
):
730
44
. .
12.
Eisenhauer
EA
,
Therasse
P
,
BogaertsSchwartz
JLH
,
Schwartz
LH
,
Sargent
D
,
Ford
R
,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009
;
45
(
2
):
228
47
. .
13.
Heng
DY
,
Wells
JC
,
RiniBeuselinck
BIB
,
Beuselinck
B
,
Lee
JL
,
Knox
JJ
,
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium
.
Eur Urol
.
2014
;
66
(
4
):
704
10
. .
14.
Méjean
A
,
Ravaud
A
,
ThezenasColas
SS
,
Colas
S
,
Beauval
J-B
,
Bensalah
K
,
Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma
.
N Engl J Med
.
2018
;
379
(
5
):
417
27
. .
15.
Donskov
F
,
Michaelson
MD
,
Puzanov
I
,
Davis
MP
,
Bjarnason
GA
,
Motzer
RJ
,
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
.
Br J Cancer
.
2015
;
113
(
11
):
1571
80
. .
16.
Mosca
A
,
De Giorgi
U
,
Procopio
G
,
Basso
U
,
Cartenì
G
,
Bersanelli
M
,
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the “Pamerit” study
.
Jpn J Clin Oncol
.
2020 Nov 20
. .
17.
Kucharz
J
,
Dumnicka
P
,
Giza
A
,
Demkow
U
,
Kusnierz-Cabala
B
,
Demkow
T
,
Radiological response and neutrophil-to-lymphocyte ratio as predictive factors for progression-free and overall survival in metastatic renal cell carcinoma patients treated with sunitinib
.
Adv Exp Med Biol
.
2019
;
1153
:
31
45
. .
18.
Motzer
RJ
,
Escudier
B
,
McDermott
DF
,
Arén Frontera
O
,
Melichar
B
,
Powles
T
,
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
.
J Immunother Cancer
.
2020
;
8
(
2
):
e000891
. .
19.
De Giorgi
U
,
Scarpi
E
,
Sacco
C
,
Aieta
M
,
Lo Re
G
,
Sava
T
,
Standard vs. adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis
.
Clin Genitourin Cancer
.
2014
;
12
(
3
):
182
9
.
20.
Kanesvaran
R
,
Saux
OL
,
Motzer
R
,
Choueiri
TK
,
Scotté
F
,
Bellmunt
J
,
Elderly patients with metastatic renal cell carcinoma: position paper from the international society of geriatric oncology
.
Lancet Oncol
.
2018
;
19
(
6
):
e317
26
. .
21.
Pierantoni
F
,
Basso
U
,
Maruzzo
M
,
Lamberti
E
,
Bimbatti
D
,
Tierno
G
,
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience
.
J Geriatr Oncol
.
2020 Sep 21
. S1879-4068(20)30436-7.
22.
Sternberg
CN
,
Calabrò
F
,
Bracarda
S
,
Cartenì
G
,
Lo Re
G
,
Ruggeri
EM
,
Safety and Efficacy of sunitinib in patients from Italy with Metastatic Renal Cell carcinoma: final results from an Expanded-Access Trial
.
Oncology
.
2015
;
88
(
5
):
273
80
. .
23.
Procopio
G
,
Prisciandaro
M
,
Iacovelli
R
,
Cortesi
E
,
Fornarini
G
,
Facchini
G
,
Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian Managed Access Program
.
Clin Genitourin Cancer
.
2018
;
16
(
4
):
e945
51
. .
24.
Nardone
B
,
Hensley
JR
,
Kulik
L
,
West
DP
,
Mulcahy
M
,
Rademaker
A
,
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life
.
J Drugs Dermatol
.
2012
;
11
(
11
):
e61
5
.
25.
Chaar
M
,
Kamta
J
,
Ait-Oudhia
S
.
Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
.
Onco Targets Ther
.
2018
;
11
:
6227
37
. .
26.
Motzer
RJ
,
Tannir
NM
,
McDermott
DF
,
Arén Frontera
O
,
Melichar
B
,
Choueiri
TK
,
CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
.
N Engl J Med
.
2018
;
378
:
1277
90
.
27.
Rini
BI
,
Plimack
ER
,
Stus
V
,
Gafanov
R
,
Hawkins
R
,
Nosov
D
,
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
.
N Engl J Med
.
2019
;
380
(
12
):
1116
27
. .
28.
NCCN guidelines for Renal Cell Carcinoma. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 2021 Feb 6.
30.
Aeppli
S
,
Schmaus
M
,
Eisen
T
,
Escudier
B
,
Grünwald
V
,
Larkin
J
,
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
.
ESMO Open
.
2021
;
6
(
1
):
100030
. .
31.
Motzer
RJ
,
Banchereau
R
,
Hamidi
H
,
Powles
T
,
McDermott
D
,
Atkins
MB
,
Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade
.
Cancer Cell
.
2020
;
38
(
6
):
803
17.e4
. .
32.
Albiges
L
,
Barthélémy
P
,
Gross-Goupil
M
,
Negrier
S
,
Needle
MN
,
Escudier
B
.
TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma
.
Ann Oncol
.
2021
;
32
(
1
):
97
102
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.